Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)

Next Previous
Trial Profile

Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 24 May 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amantadine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Therapeutic Use
  • Acronyms EASED
  • Sponsors Adamas Pharmaceuticals

Most Recent Events

  • 18 May 2018 Results of pooled data from 2 phase1 trial and a phase 2/3 trial assessing pharmacokinetics of ADS-5102 (Amantadine) extended release capsules administered once daily at bedtime for the treatment of dyskinesia, were published in the Clinical Pharmacokinetics.
  • 27 Apr 2018 Results presented at the 70th Annual Meeting of the American Academy of Neurology
  • 24 Aug 2017 According to an Adamas Pharmaceuticals media release, the U.S. Food and Drug Administration (FDA) has approved GOCOVRI (amantadine) extended release capsules for treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top